Next-gen obesity biotech Metsera has filed to debut on the public markets, proposing an IPO nine months after emerging. | ...

Weight-loss drug developer Metsera, backed by ARCH Venture Partners, revealed a wider loss in its paperwork for a U.S.

From once-weekly subcutaneously injectable medicines agonizing the glucagon-like peptide 1 receptor (GLP-1R), longer-acting ...

Metsera has linked its GLP-1 drug candidate to weight loss of up to 11.3% after 12 weeks, encouraging the biotech to use some ...

The New York company is hoping to enter the GLP-1RA space with its newest offering requiring dosing every month over ...

Metsera has filed for an initial public offering. The clinical-stage biopharmaceutical company submitted a registration statement to regulators on Friday, saying it intends to list under the ticker ...

Metsera files for IPO, developing GLP-1 drug MET-097i and other obesity treatments to compete with Eli Lilly and Novo Nordisk ...

The startup, which has already raised more than half a billion dollars, released Phase 2 results that could position its drug ...

In a rare move, the FDA recommended a minimum of 5% weight-loss for drug developers seeking to establish the efficacy of ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/97.B9uuF-Zi.js ...

NEW YORK, January 07, 2025--(BUSINESS WIRE)--Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today ...

Dutch paint and coatings maker AkzoNobel plans to lay off of up to 211 staff in France, about 16% of its workforce in the ...